Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS

Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval under exceptional circumstances of recombinant ADAMTS13 rADAMTS13 for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP.

Related Keywords

Japan , Osaka , United States , Japanese , Kremer Hovinga , Jun Saito , Van Dorland , Thromb Haemost , Takeda Pharmaceutical Company Limited , Exchange Commission , Japanese Ministry Of Health , European Medicines Agency , European Commission , Treatment Options , Drug Administration , European Union , Franchise Global Program Leader At Takeda , Committee For Medicinal Products Human Use , Potentially Fatal Blood Clotting Disorder , Limited Treatment Options , Mortality Rate , Only Recombinant , Replacement Therapy , Opinion Based , Including Results , First Randomized , Crossover Phase , Medicinal Products , Human Use , Obi Umeh , Vice President , Franchise Global Program Leader , New England Journal , Japanese Ministry , Orphan Drug Designation , Fast Track , Rare Pediatric Disease , Rare Pediatric Disease Voucher , Annual Report , Rev Dis , Thrombotic Thrombocytopenic , Media Contact ,